Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at No
Validation Results Using a Plasma-based Targeted Methylation Assay Demonstrate Potential to Identify High-Risk Patients who Might Benefit From Additional TreatmentMENLO PARK, Calif. & CAMBRIDGE, England & SEOUL, South Korea--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early wh...
Source: pharmiweb.com